BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 17415646)

  • 1. Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients.
    Johansson JE; Ekman T
    Dig Dis Sci; 2007 Sep; 52(9):2340-5. PubMed ID: 17415646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
    Johansson JE; Brune M; Ekman T
    Bone Marrow Transplant; 2001 Oct; 28(8):737-42. PubMed ID: 11781624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.
    Goldberg J; Jacobsohn DA; Zahurak ML; Vogelsang GB
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):101-7. PubMed ID: 15682070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
    Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
    Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
    Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
    Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
    Zhu K; Xu Y; Wu D; Xu X; Huang L
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):403-5. PubMed ID: 11877010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
    Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation.
    Shikari H; Amparo F; Saboo U; Dana R
    Cornea; 2015 Mar; 34(3):243-7. PubMed ID: 25603230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of acute graft-versus-host disease in the risk of bacteremia and invasive fungal disease after allogeneic hemopoietic stem cell transplantation in children. Results from a single-center observational study.
    Castagnola E; Bagnasco F; Bandettini R; Caviglia I; Morreale G; Lanino E; Giardino S; Moroni C; Haupt R; Faraci M
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1068-73. PubMed ID: 24691219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
    Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.